| Find a Doctor, Researcher, or Specialist
Search here by name, specialty, or department |
 |
 |
 |
Caroline Hastings, MD
Pediatric Hematology-Oncology
Director, Fellowship Program, Graduate Medical Education
Research & PublicationsCLINICAL SPECIALTIES: cancer, tumors, sarcoma, chemotherapy, targeted therapy, brain and spinal cord tumors, pediatric oncology, hepatoblastoma, Wilms tumor blood and bone marrow cancers, blood disorders, anemia, clotting disorders, sickle cell disease, hemophilia, leukemia and lymphoma, Hodgkins and non-Hodgkins, stem cell transplantation
|
|
|
Department Location
Oncology
Main Hospital
747 52nd Street
Oakland, CA 94609
Phone: 510-428-3372
Hematology Oncology
Walnut Creek Campus
2401 Shadelands Drive
Walnut Creek, CA 94598
Phone: (510) 428-3372
Oncology
Reno Clinic
5301 Reno Corporate Dr.
Reno, NV 89511
Phone: 510-428-3372
|
|
Referrals & Immediate Consults
Referring Physicians should phone the specialty department directly and speak with the specialist on call.
Evenings/Weekends: Phone: 510-428-3000 Ask to be connected to the department's specialist on call.
Appointments
Please request a referral from your physician. |
|
|
|
Education & Training
|
Medical School University of California, Davis, CA Residency Children's Hospital & Research Center Oakland, CA (Pediatrics) |
Board Certification Pediatric Hematology-Oncology, American Board of Pediatrics Fellowship Children's Hospital & Research Center Oakland, CA (Pediatric Hematology Oncology) |
|
Additional Information | Dr. Hastings is a senior clinician-scientist and educator. She is one of the leaders of the Hematology Oncology Division. She is the Director of the Pediatric Hematology Oncology Fellowship Program, and the Director of the hospital-wide fellowship education program. On a national level, she is a leader in ASPHO and an elected trustee to the board. She is actively involved in oversight of the career domains including the Professional Development Training Program and Practice committees.
Dr. Hastings is the Director of our Outreach Program, including Shadelands-Walnut Creek, Reno (Nevada), and Napa. Dr. Hastings was the co-founder of our multidisciplinary Pediatric Neuro-Oncology Program in 2004. Her skill set in program building has led to her selection in 2015 as an Associate Medical Director for the pediatric network development group for both UCSF Benioff Children’s Hospitals.
Dr. Hastings has several academic interests, including relapsed extramedullary acute lymphoblastic leukemia and Niemann Pick Type C disease. She has been an active member of many COG committees in leukemia and supportive care, and has been co-chair of an ALL extramedullary relapse study.
After developing a compassionate use clinical program for Niemann-Pick Type C Disease, she developed a research program for this disease. She is the principal investigator for FDA-approved new treatment for Niemann-Pick Type C, and has with colleagues been studying amyloid-beta metabolism, iron hemostasis and biomarkers in Niemann-Pick. She will serve as the international advisor in a Phase I/II trial as well as a Phase I trial based at BCHO in early 2017. These studies will focus on the treatment of NPC with Trappsol® Cyclo™ hydroxypropyl-β-cyclodextrin given intravenously and will seek to determine pharmacokinetics, pharmacodynamics, and understand mechanism of disease and effect on outcomes.
She is a tireless volunteer with many national organizations advocating for children with cancer, including the American Cancer Society's childhood cancer survivors college scholarship (served as the chair for 12 years), local and national St. Baldrick’s Foundation activities, and several non-profits aimed at improving quality of life for cancer patients and their families. She has led the local BCHO St. Baldrick’s fund raising event for over 10 years and it continues to be one of the events with most funds raised in the country. She is also involved with philanthropic programs to raise awareness and funds to support research and care in childhood cancer.
Selected books and publications:
- Zweidler-McKay P, Hogan MJ, Jubran RF, Black V, Casillas J, Harper J, Malempati S, Margolin J, Felgenhauer J, Sakamoto K, Franklin J, Shah M, Seibel N, Buchanan G, Vaiselbuh S, Hastings C, Hilden J, Stork L. Navigating your career path in pediatric hematology/oncology (PHO): On and off the beaten path. Pediatr Blood Cancer 2016;00:1-10.
- Feusner JH, Hastings CA, Agrawal AK, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin Springer; 2015.
- Hastings C, Gaynon PS, Nachman JB, Sather HN, Lu X, Devidas M, Seibel NL. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (>/=200 x 10 /l) with T cell acute lymphoblastic leukaemia but not B cell disease: A report from the Children's Oncology Group. Br J Haematol 2015.
- Te Vruchte D, Speak AO, Wallom KL, Al Eisa N, Smith DA, Hendriksz CJ, Simmons L, Lachmann RH, Cousins A, Hartung R, Mengel E, Runz H, Beck M, Amraoui Y, Imrie J, Jacklin E, Riddick K, Yanjanin NM, Wassif CA, Rolfs A, Rimmele F, Wright N, Taylor C, Ramaswami U, Cox TM, Hastings C, Jiang X, Sidhu R, Ory DS, Arias B, Jeyakumar M, Sillence DJ, Wraith JE, Porter FD, Cortina-Borja M, Platt FM. Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J Clin Invest 2014.
- Hung YH, Faux NG, Killilea DW, Yanjanin N, Firnkes S, Volitakis I, Ganio G, Walterfang M, Hastings C, Porter FD, Ory DS, Bush AI. Altered transition metal homeostasis in Niemann-Pick disease, type C1. Metallomics, 2013. DOI:10.1039/c3mt00308f. PMID: 24343124
- Hastings C, Torkildson J, Anurag A. Handbook of Pediatric Hematology Oncology: The Children’s Hospital & Research Center Oakland, 2nd edition, Wiley-Blackwell, 2012.
- Mattson N, Olsson M, Gustavsson MK, Kosicek M, Malnar M, Månsson, JE, Blomqvist M, Gobom J, Andreasson U, Brinkmalm G, Vite C, Hecimovic S, Hastings C, Blennow K, Zetterberg H, Portelius E. Amyloid-β metabolism in Niemann-Pick C disease models and patients. Metabolic Brain Disease, e-pub Sept 1, 2012. PMID: 22935999
- Hastings C, Torkildson J, Raphael R. Intrathecal Hydroxy-Propyl-Beta-Cyclodextrin Reverses Hearing Loss in Identical Twin Girls with Niemann-Pick Type C Disease. [abstract] Mol Gen Metabolism. 2012;105(2):S34.
- Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, Mattano LA, Sather H, Devidas M, Fryer DR, Steinhertz PG, Seibel NL. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive post induction treatment: A report from the Children’s Oncology Group. J Clin Oncol. 2009 Nov 1;27(31):5189-94. Epub 2009 Oct 5.
- Seibel NL, Steinhertz PG, Sather HN, Nachman JB, DeLaat C, Ettinger LJ, Freyer DR, Mattano LA, Hastings C, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La, MK, Edens C, Gaynon PS. Early post-intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Blood. 2008;111(5):2548.
- Hastings C, Wechsler DS, Stine KC, Graham DK, Abshire T. Consensus on a core curriculum in American training programs in Pediatric hematology-oncology: A report from the ASPHO training committee. Pediatr Hematology and Oncology, 24:503-512, 2007.
- Badawy SM, Black V, Meier ER, Myers KC, Pinkney K, Hastings C, Hilden JM, Zweidler-McKay P, Stork, L, Johnson T, Vaiselbuh SR. Early career mentoring through the American Society of Pediatric Hematology Oncology: Lessons learned from a pilot program. Pediatr Blood Cancer 2016;Sept. DOI: 10.1002/pbc.26252 [Epub 2016 ahead of print] PMID: 27616578.
|
|
|
|
|
|
|
|
|
|
|